Table 3.
Cox analysis for risk factors for an acute exacerbation of idiopathic pulmonary fibrosis
| HR | (95 % CI) | P Value | |
|---|---|---|---|
| Treatment after the diagnosis | |||
| Immunosuppressive agent | |||
| Unadjusted | 3.35 | (1.27 to 8.84) | 0.014 |
| Cardiovascular diseases | |||
| Unadjusted | 2.49 | (1.00 to 6.19) | 0.049 |
| Adjusteda | 3.21 | (1.24 to 8.32) | 0.016 |
| GAP stage (≥II) | |||
| Unadjusted | 3.88 | (1.54 to 9.80) | 0.004 |
| Adjusteda | 3.23 | (1.22 to 8.51) | 0.018 |
| Serum markers | |||
| LDH, U/L, Cut off point = 180 | |||
| Unadjusted | 4.00 | (0.92 to 17.46) | 0.065 |
| Adjusteda | 3.49 | (0.78 to 15.57) | 0.101 |
| KL-6, U/mL, Cut off point = 946 | |||
| Unadjusted | 1.57 | (0.67 to 3.68) | 0.296 |
| Adjusteda | 1.53 | (0.65 to 3.59) | 0.326 |
| SP-D, ng/mL, Cut off point = 194.7 | |||
| Unadjusted | 3.17 | (1.21 to 8.31) | 0.019 |
| Adjusteda | 2.69 | (0.98 to 7.42) | 0.056 |
| BAL fluid findings | |||
| Lymphocytes, %, Cut off point = 10.15 | |||
| Unadjusted | 2.01 | (0.89 to 4.52) | 0.091 |
| Adjusteda | 2.03 | (0.90 to 4.57) | 0.087 |
| Neutrophils, %, Cut off point = 1.77 | |||
| Unadjusted | 4.04 | (0.92 to 17.79) | 0.065 |
| Adjusteda | 3.54 | (0.79 to 15.94) | 0.100 |
| Eosinophils, %, Cut off point = 3.21 | |||
| Unadjusted | 3.27 | (1.29 to 8.29) | 0.013 |
| Adjusteda | 2.89 | (1.11 to 7.51) | 0.029 |
Abbreviations: HR hazard ratio, CI confidence interval, GAP gender-age-physiology, LDH lactate dehydrogenase, KL-6 Krebs von den Lungen-6, SP-D surfactant protein-D, BAL bronchoalveolar lavage
aAdjusted for immunosuppressive agent therapy